107 related articles for article (PubMed ID: 21429564)
1. Prolonged half-life of glycoPEGylated rFVIIa variants compared to native rFVIIa.
Karpf DM; Sørensen BB; Hermit MB; Holmberg HL; Tranholm M; Bysted BV; Groth AV; Bjørn SE; Stennicke HR
Thromb Res; 2011 Aug; 128(2):191-5. PubMed ID: 21429564
[TBL] [Abstract][Full Text] [Related]
2. Prolonged effect of GlycoPEGylated rFVIIa (40k-PEG-rFVIIa) in rabbits correlates to activity in plasma.
Johansen PB; Bjørn SE; Agersø H; Thorup I; Hermit MB; Sørensen B; Stennicke HR; Ezban M; Tranholm M
Thromb Haemost; 2010 Jul; 104(1):157-64. PubMed ID: 20390231
[TBL] [Abstract][Full Text] [Related]
3. Activity and regulation of glycoPEGylated factor VIIa analogs.
Ghosh S; Sen P; Pendurthi UR; Rao LV
J Thromb Haemost; 2008 Sep; 6(9):1525-33. PubMed ID: 18624982
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics and pharmacodynamics of rFVIIa and new improved bypassing agents for the treatment of haemophilia.
Agersø H; Tranholm M
Haemophilia; 2012 Jul; 18 Suppl 5():6-10. PubMed ID: 22757678
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics and pharmacodynamics of recombinant factor VIIa.
Lindley CM; Sawyer WT; Macik BG; Lusher J; Harrison JF; Baird-Cox K; Birch K; Glazer S; Roberts HR
Clin Pharmacol Ther; 1994 Jun; 55(6):638-48. PubMed ID: 8004880
[TBL] [Abstract][Full Text] [Related]
6. Prediction of human pharmacokinetics of activated recombinant factor VII and B-domain truncated factor VIII from animal population pharmacokinetic models of haemophilia.
Larsen MS; Juul RV; Groth AV; Simonsson USH; Kristensen AT; Knudsen T; Agersø H; Kreilgaard M
Eur J Pharm Sci; 2018 Mar; 115():196-203. PubMed ID: 29369801
[TBL] [Abstract][Full Text] [Related]
7. Monitoring rFVIIa 90 μg kg⁻¹ dosing in haemophiliacs: comparing laboratory response using various whole blood assays over 6 h.
Brophy DF; Martin EJ; Christian Barrett J; Nolte ME; Kuhn JG; Gerk PM; Carr ME; Pelzer H; Agersø H; Ezban M; Hedner U
Haemophilia; 2011 Sep; 17(5):e949-57. PubMed ID: 21362113
[TBL] [Abstract][Full Text] [Related]
8. The molar hydrodynamic volume changes of factor VIIa due to GlycoPEGylation.
Plesner B; Westh P; Hvidt S; Nielsen AD
J Pharm Biomed Anal; 2011 Jun; 55(3):597-602. PubMed ID: 21429688
[TBL] [Abstract][Full Text] [Related]
9. Clearance of rFVIIa and NN1731 after intravenous administration to Beagle dogs.
Agersø H; Kristensen NR; Østergaard H; Karpf DM; Hermit MB; Pelzer H; Petersen LC; Ezban M
Eur J Pharm Sci; 2011 Apr; 42(5):578-83. PubMed ID: 21382491
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics and safety of a 270 mcg kg-1 dose of room temperature stable recombinant activated factor VII in patients with haemophilia.
Morfini M; Bjerre J
Haemophilia; 2011 Nov; 17(6):860-6. PubMed ID: 21371194
[TBL] [Abstract][Full Text] [Related]
11. Clinical trial to investigate the pharmacokinetics, pharmacodynamics, safety, and efficacy of recombinant factor VIIa in Japanese patients with hemophilia with inhibitors.
Shirahata A; Kamiya T; Takamatsu J; Kojima T; Fukutake K; Arai M; Hanabusa H; Tagami H; Yoshioka A; Shima GM; Naka GH; Fujita GS; Minamoto Y; Kamizono J; Saito H
Int J Hematol; 2001 Jun; 73(4):517-25. PubMed ID: 11503968
[TBL] [Abstract][Full Text] [Related]
12. Pharmacological characteristics of a novel, recombinant fusion protein linking coagulation factor VIIa with albumin (rVIIa-FP).
Zollner S; Schuermann D; Raquet E; Mueller-Cohrs J; Weimer T; Pragst I; Dickneite G; Schulte S
J Thromb Haemost; 2014 Feb; 12(2):220-8. PubMed ID: 24641308
[TBL] [Abstract][Full Text] [Related]
13. Enhanced Pharmacokinetics of Factor VIIa as a Monomeric Fc Fusion.
Salas J; Liu T; Lu Q; Kulman JD; Ashworth T; Kistanova E; Moore N; Pierce GF; Jiang H; Peters R
Thromb Res; 2015 May; 135(5):970-6. PubMed ID: 25721936
[TBL] [Abstract][Full Text] [Related]
14. Effect of glycoPEGylation on factor VIIa binding and internalization.
Sen P; Ghosh S; Ezban M; Pendurthi UR; Vijaya Mohan Rao L
Haemophilia; 2010 Mar; 16(2):339-48. PubMed ID: 19845776
[TBL] [Abstract][Full Text] [Related]
15. 40K glycoPEGylated, recombinant FVIIa: 3-month, double-blind, randomized trial of safety, pharmacokinetics and preliminary efficacy in hemophilia patients with inhibitors.
Ljung R; Karim FA; Saxena K; Suzuki T; Arkhammar P; Rosholm A; Giangrande P;
J Thromb Haemost; 2013 Jul; 11(7):1260-8. PubMed ID: 23578227
[TBL] [Abstract][Full Text] [Related]
16. Prophylactic treatment of haemophilia patients with inhibitors: clinical experience with recombinant factor VIIa in European Haemophilia Centres.
Morfini M; Auerswald G; Kobelt RA; Rivolta GF; Rodriguez-Martorell J; Scaraggi FA; Altisent C; Blatny J; Borel-Derlon A; Rossi V
Haemophilia; 2007 Sep; 13(5):502-7. PubMed ID: 17880436
[TBL] [Abstract][Full Text] [Related]
17. Results of the WIRK prospective, non-interventional observational study of recombinant activated factor VII (rFVIIa) in patients with congenital haemophilia with inhibitors and other bleeding disorders.
Birschmann I; Klamroth R; Eichler H; Schenk J; Kirchmaier CM; Halimeh S
Haemophilia; 2013 Sep; 19(5):679-85. PubMed ID: 23647644
[TBL] [Abstract][Full Text] [Related]
18. GlycoPEGylated rFVIIa (N7-GP) has a prolonged hemostatic effect in hemophilic mice compared with rFVIIa.
Holmberg H; Elm T; Karpf D; Tranholm M; Bjørn SE; Stennicke H; Ezban M
J Thromb Haemost; 2011 May; 9(5):1070-2. PubMed ID: 21366858
[No Abstract] [Full Text] [Related]
19. Prolonged half-life and preserved enzymatic properties of factor IX selectively PEGylated on native N-glycans in the activation peptide.
Østergaard H; Bjelke JR; Hansen L; Petersen LC; Pedersen AA; Elm T; Møller F; Hermit MB; Holm PK; Krogh TN; Petersen JM; Ezban M; Sørensen BB; Andersen MD; Agersø H; Ahmadian H; Balling KW; Christiansen ML; Knobe K; Nichols TC; Bjørn SE; Tranholm M
Blood; 2011 Aug; 118(8):2333-41. PubMed ID: 21700771
[TBL] [Abstract][Full Text] [Related]
20. Feasibility of using recombinant factor VIIa in continuous infusion.
Schulman S; Bech Jensen M; Varon D; Keller N; Gitel S; Horoszowski H; Heim M; Martinowitz U
Thromb Haemost; 1996 Mar; 75(3):432-6. PubMed ID: 8701403
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
